Comparative effectiveness of spirapril and enalapril in patients with coronary heart disease-caused chronic heart failure
Aim. During prospective 6-month follow-up, to compare spirapril and enalapril effectiveness in patients with coronary heart disease (CHD)-caused chronic heart failure (CHF). Material and methods. In total, 61 patients with CHD-caused CHF, according to inclusion/exclusion criteria, were divided into...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1242 |
| Summary: | Aim. During prospective 6-month follow-up, to compare spirapril and enalapril effectiveness in patients with coronary heart disease (CHD)-caused chronic heart failure (CHF). Material and methods. In total, 61 patients with CHD-caused CHF, according to inclusion/exclusion criteria, were divided into spirapril group (n=29; mean dose 5±1.3 mg/d) and enalapril group (n=32, mean dose 18.3±9.0 mg/ d). At baseline and after 6-month follow-up, all patients underwent general clinical examination, 6-minute walking test, echocardiography (EchoCG), and quantitative measurement of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level. Data analysis was performed with STATISTICA package (Version 6.0). Results. Both agents had similar clinical effects: during follow-up, left ventricular ejection fraction (LVEF) increased by 9.6% in spirapril group (р=0.00013), and by 7.0% in enalapril group (р=0.01). In 6-minute walking test, the distance walked increased by 25.1% (р=0.00016) and 14.8% (р=0.01), respectively. NT-proBNP levels significantly correlated with patients’ functional status, assessed in 6-minute walking test (r=-0.43, p=0.002), and EchoCG-assessed LF systolic dysfunction (r=-0.46, p=0.001). In both groups, NT-proBNP levels had raised: non-significantly, up to 25 pmol/l (р=0.66) in spirapril group, and significantly, up to 150 pmol/l (р=0.045), in enalapril group. Conclusion. In patients with CHD-caused CHF, spirapril was as clinically effective as a traditionally administered ACE inhibitor. Spirapril was more effective in delaying NT-proBNP level increase. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |